• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.

作者信息

Vittorio Alexander, Sharma Rajiv, Siejka Dylan, Bhattarai Keshav, Hardikar Ashutosh

机构信息

Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia; Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia.

Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia.

出版信息

Clin Lung Cancer. 2018 Sep;19(5):e717-e720. doi: 10.1016/j.cllc.2018.05.010. Epub 2018 May 26.

DOI:10.1016/j.cllc.2018.05.010
PMID:29937384
Abstract
摘要

相似文献

1
Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.接受纳武单抗治疗转移性肺腺癌时出现复发性心包积液：病例报告及文献复习
Clin Lung Cancer. 2018 Sep;19(5):e717-e720. doi: 10.1016/j.cllc.2018.05.010. Epub 2018 May 26.
2
Pericardial effusion under nivolumab: case-reports and review of the literature.纳武利尤单抗致心包积液：病例报告及文献复习。
J Immunother Cancer. 2019 Oct 18;7(1):266. doi: 10.1186/s40425-019-0760-4.
3
Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion.纳武单抗诱导的心包填塞：一例报告及讨论
Cardiology. 2017;136(1):49-51. doi: 10.1159/000447053. Epub 2016 Aug 24.
4
Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report.肺癌患者使用纳武利尤单抗治疗期间并发心脏压塞并心包内博来霉素治疗：病例报告。
Immunotherapy. 2019 Apr;11(6):467-472. doi: 10.2217/imt-2019-0003. Epub 2019 Feb 7.
5
Pericardial effusion with tamponade physiology induced by nivolumab.由纳武单抗引起的伴有心包填塞生理学改变的心包积液。
Int J Cardiol. 2016 Nov 1;222:613-614. doi: 10.1016/j.ijcard.2016.08.023. Epub 2016 Aug 3.
6
Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.患者在接受帕博利珠单抗治疗期间发生心包填塞：病例报告及文献复习。
Thorac Cancer. 2020 May;11(5):1350-1353. doi: 10.1111/1759-7714.13399. Epub 2020 Mar 17.
7
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.免疫治疗的晚期非小细胞肺癌患者的心包积液发生率。
Adv Ther. 2020 Jul;37(7):3178-3184. doi: 10.1007/s12325-020-01386-y. Epub 2020 May 20.
8
Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.免疫介导性心包炎伴心包填塞在纳武利尤单抗治疗期间。
J Immunother. 2018 Sep;41(7):329-331. doi: 10.1097/CJI.0000000000000217.
9
Cardiac tamponade in a patient with stage IV lung adenocarcinoma treated with pembrolizumab.接受派姆单抗治疗的 IV 期肺腺癌患者发生心脏压塞。
Immunotherapy. 2019 Dec;11(18):1533-1540. doi: 10.2217/imt-2019-0067. Epub 2019 Dec 9.
10
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab.纳武利尤单抗治疗 94 周期后出现的迟发性胸腔和心包积液：免疫相关不良事件。
Intern Med. 2021 Nov 15;60(22):3585-3588. doi: 10.2169/internalmedicine.7219-21. Epub 2021 Jun 5.

引用本文的文献

1
[Advances in Pseudoprogression of Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].[免疫检查点抑制剂在非小细胞肺癌中假性进展的研究进展]
Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):306-320. doi: 10.3779/j.issn.1009-3419.2024.101.10.
2
Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.使用日本真实世界数据库评估纳武单抗的心脏不良事件
Clin Drug Investig. 2023 Mar;43(3):177-184. doi: 10.1007/s40261-023-01246-x. Epub 2023 Feb 13.
3
Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?
免疫疗法的加入会影响恶性心包积液患者的预后吗？
Front Oncol. 2022 May 6;12:871132. doi: 10.3389/fonc.2022.871132. eCollection 2022.
4
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.免疫检查点抑制剂相关的心脏毒性：一项系统评价。
Cancers (Basel). 2021 Oct 18;13(20):5218. doi: 10.3390/cancers13205218.
5
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab.纳武利尤单抗治疗 94 周期后出现的迟发性胸腔和心包积液：免疫相关不良事件。
Intern Med. 2021 Nov 15;60(22):3585-3588. doi: 10.2169/internalmedicine.7219-21. Epub 2021 Jun 5.
6
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.免疫检查点抑制剂相关心包疾病：病例报告的系统评价
Cancer Immunol Immunother. 2021 Oct;70(10):3041-3053. doi: 10.1007/s00262-021-02938-z. Epub 2021 Apr 20.
7
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.多国癌症支持治疗协会（MASCC）2020 年免疫相关不良反应管理临床实践建议：肺毒性。
Support Care Cancer. 2020 Dec;28(12):6145-6157. doi: 10.1007/s00520-020-05708-2. Epub 2020 Sep 3.
8
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.非小细胞肺癌全身治疗的心血管并发症
J Clin Med. 2020 Apr 27;9(5):1268. doi: 10.3390/jcm9051268.
9
Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.患者在接受帕博利珠单抗治疗期间发生心包填塞：病例报告及文献复习。
Thorac Cancer. 2020 May;11(5):1350-1353. doi: 10.1111/1759-7714.13399. Epub 2020 Mar 17.
10
Pericardial effusion under nivolumab: case-reports and review of the literature.纳武利尤单抗致心包积液：病例报告及文献复习。
J Immunother Cancer. 2019 Oct 18;7(1):266. doi: 10.1186/s40425-019-0760-4.